Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer.

ABSTRACT:

Purpose

In research settings, circulating tumor DNA (ctDNA) shows promise as a tumor-specific biomarker for pancreatic ductal adenocarcinoma (PDAC). This study aims to perform analytical and clinical validation of a KRAS ctDNA assay in a Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathology-certified clinical laboratory.

Experimental design

Digital-droplet PCR was used to detect the major PDAC-associated somatic KRAS mutations (G12D, G12V, G12R, and Q61H) in liquid biopsies. For clinical validation, 290 preoperative and longitudinal postoperative plasma samples were collected from 59 patients with PDAC. The utility of ctDNA status to predict PDAC recurrence during follow-up was assessed.

Results

ctDNA was detected preoperati

SUBMITTER: Groot VP 

PROVIDER: S-EPMC7403524 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature